Page 9 - Read Online
P. 9

Cavaller-Bellaubi et al. Rare Dis Orphan Drugs J 2024;3:23          Rare Disease and
               DOI: 10.20517/rdodj.2023.58
                                                                            Orphan Drugs Journal




               Perspective                                                                   Open Access



               Framing the European Rare Diseases field through a
               structured movement of patient organisations


               Maria Cavaller-Bellaubi  , Virginie Hivert, Roseline Favresse, Yann Le Cam

               EURORDIS - Rare Diseases Europe, Paris 75014, France.
               Correspondence to: Maria Cavaller-Bellaubi, Sant Antoni Maria Claret 167, Barcelona 08025, Spain. E-mail:
               maria.cavaller@eurordis.org

               How to cite this article: Cavaller-Bellaubi M, Hivert V, Favresse R, Le Cam Y. Framing the European Rare Diseases field through a
               structured movement of patient organisations. Rare Dis Orphan Drugs J 2024;3:23. https://dx.doi.org/10.20517/rdodj.2023.58

               Received: 16 Dec 2023  First Decision: 10 Apr 2024  Revised: 28 Jun 2024  Accepted: 26 Jul 2024  Published: 31 Jul 2024

               Academic Editors: Jacques S. Beckmann, Anneliene Jonker  Academic Editor: Fangling Lan  Production Editor: Fangling Lan

               Abstract
               EURORDIS-Rare Diseases Europe is an alliance of patient organisations, working across countries, empowering
               patients with trainings, and generating evidence through surveys. It advocates for the needs of people living with
               rare diseases in Europe, influencing policy, legislation, research, healthcare services, social inclusion, medicines
               development and access. Since its creation, EURORDIS has maintained a global perspective. By nature of the rarity
               of these conditions, knowledge and expertise are scattered, so collaboration on a global level is required to have an
               understanding of disease progression. Thus, every rare disease patient group must be equipped to collaborate
               beyond its own borders. EURORDIS impacts global activities with a focus on raising awareness; empowering a
               global alliance; supporting international, national and regional initiatives; and recognising rare diseases within the
               international community while fostering collaboration among stakeholders. For these reasons, the organisation’s
               impact extends beyond Europe, as demonstrated by its international partnerships. This perspective paper explores
               EURORDIS’ achievements over two decades, examining its role in shaping policies and regulations, to demonstrate
               the vital importance of global collaboration in the rare disease field. Looking ahead, EURORDIS’ Strategic Goals, to
               be achieved by 2030, align with the United Nations Sustainable Development Goals Agenda 2030 and advocate
               for a European Action Plan for Rare Diseases. This illustrates EURORDIS’ continued commitment to transforming
               policies into tangible outcomes. With its ongoing dedication, collaborative efforts, and enduring impact on the rare
               disease community, EURORDIS remains a driving force for positive change in the lives of people living with rare
               diseases.

               Keywords: Rare diseases, patient organisations, ecosystem, policy, framework, empowerment, advocacy,
               partnership




                           © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0
                           International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
                           adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
               long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
               indicate if changes were made.

                                                                                       www.oaepublish.com/rdodj
   4   5   6   7   8   9   10   11   12   13   14